ABUS Arbutus Biopharma Corporation - Common Stock
$5,01
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 12, 2026
Rango 52S
$3–$5
82% of range
Calificación del Analista
BUY
8 analysts
Precio Objetivo
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
Margen de Beneficio Neto
-237.9%
Acerca de Arbutus Biopharma Corporation - Common Stock Descripción general de la empresa de Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Leer más
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
ABUS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$5.01
Capitalización Bursátil
$987M
P/E (TTM)
-30.1
BPA (TTM)
$-0.17
Ingresos (TTM)
$14M
Rendimiento div.
—
ROE
-42.0%
Deuda/Capital
—
Rango 52S
$3 – $5
ABUS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$14M
2016-12-31
→
2025-12-31
BPA
$-0.17
2016-12-31
→
2025-12-31
Flujo de caja libre
$-40M
2016-12-31
→
2025-12-31
Márgenes
-237.9%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
ABUS
Mediana de Pares
P/E (TTM)
-30.1
6.7
P/S (TTM) (P/V (TTM))
70.1
39.8
P/B (P/C)
12.9
4.8
Price / FCF (Precio / FCF)
-24.9
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
ABUS
Mediana de Pares
Operating Margin (Margen Operativo)
-271.0%
—
Net Profit Margin (Margen de Beneficio Neto)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
ABUS
Mediana de Pares
Current Ratio (Ratio corriente)
15.7
9.7
Quick Ratio (Ratio Rápido)
15.5
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
ABUS
Mediana de Pares
Revenue YoY (Ingresos interanuales)
128.2%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
-28.8%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
15.3%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
ABUS
Mediana de Pares
ABUS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
8 analistas
- Compra fuerte 3 37,5%
- Compra 4 50,0%
- Mantener 1 12,5%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
1 analistas · 2026-08-17
Mín
$5.53
Máx
$5.53
Objetivo mediano
$5.53
+10,3%
Objetivo medio
$5.53
+10,3%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.01%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 31 de marzo de 2026 | $-0.05 | $-0.03 | -0.02% |
| 31 de diciembre de 2025 | $-0.02 | $-0.04 | 0.02% |
| 30 de septiembre de 2025 | $-0.04 | $-0.03 | -0.01% |
| 30 de junio de 2025 | $0.01 | $-0.05 | 0.06% |
| 31 de marzo de 2025 | $-0.13 | $-0.11 | -0.02% |
| 31 de diciembre de 2024 | $-0.07 | $-0.08 | 0.01% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Balance general 25
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Flujo de Efectivo 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Liquidez y Solvencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Eficiencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Balance general 22
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Flujo de Efectivo 11
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Liquidez y Solvencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Eficiencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $14M | $6M | $18M | $39M | $11M |
| Margen Operativo % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Beneficio neto | $-34M | $-70M | $-73M | $-69M | $-76M |
| EPS Diluido | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Ratio Rápido | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-40M | $-65M | $-87M | $-36M | $-68M |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 191 declarantes · $496.0M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 41 (+15 vs trimestre anterior) | 22 (-8 vs trimestre anterior) | 55 (+10 vs trimestre anterior) | 44 (-8 vs trimestre anterior) | +14.8M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Two Seas Capital LP | $91 658 798 | 19 095 583 | 18,48% | Acciones |
| Whitefort Capital Management, LP | $75 812 453 | 15 794 261 | 15,28% | Acciones |
| VANGUARD GROUP INC | $38 412 670 | 7 986 002 | 7,74% | Acciones |
| STATE STREET CORP | $37 772 059 | 7 869 179 | 7,62% | Acciones |
| Rubric Capital Management LP | $36 158 098 | 7 532 937 | 7,29% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $33 651 259 | 7 010 679 | 6,78% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $16 983 987 | 3 537 471 | 3,42% | Acciones |
| BlackBarn Capital Partners LP | $12 000 000 | 2 500 000 | 2,42% | Acciones |
| Woodline Partners LP | $10 952 909 | 2 281 856 | 2,21% | Acciones |
| GOLDMAN SACHS GROUP INC | $8 545 829 | 1 780 381 | 1,72% | Acciones |
| Jefferies Financial Group Inc. | $8 216 026 | 1 711 672 | 1,66% | Acciones |
| NOMURA HOLDINGS INC | $7 857 989 | 1 637 081 | 1,58% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7 398 998 | 1 541 458 | 1,49% | Acciones |
| BANK OF AMERICA CORP /DE/ | $7 169 851 | 1 493 719 | 1,45% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6 869 846 | 1 431 218 | 1,38% | Acciones |
| OSAIC HOLDINGS, INC. | $6 469 756 | 1 347 866 | 1,30% | Acciones |
| ADAR1 Capital Management, LLC | $6 087 106 | 1 268 147 | 1,23% | Acciones |
| Deltroit Asset Management (UK) LLP | $5 760 000 | 1 200 000 | 1,16% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $5 449 738 | 1 135 362 | 1,10% | Acciones |
| CITIGROUP INC | $4 175 784 | 869 955 | 0,84% | Acciones |
| BANK OF MONTREAL /CAN/ | $3 734 102 | 777 938 | 0,75% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3 123 360 | 650 700 | 0,63% | Acciones |
| MACKENZIE FINANCIAL CORP | $2 946 269 | 613 806 | 0,59% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2 889 638 | 602 008 | 0,58% | Acciones |
| Western Standard LLC | $2 605 378 | 542 787 | 0,53% | Acciones |
| Rangeley Capital, LLC | $2 400 000 | 500 000 | 0,48% | Acciones |
| Man Group plc | $2 272 642 | 473 467 | 0,46% | Acciones |
| Corbin Capital Partners, L.P. | $2 231 732 | 682 487 | 0,45% | Acciones |
| CenterBook Partners LP | $2 136 725 | 445 151 | 0,43% | Acciones |
| Freestone Capital Holdings, LLC | $2 124 000 | 442 500 | 0,43% | Acciones |
| CITADEL ADVISORS LLC | $1 942 541 | 404 696 | 0,39% | Acciones |
| KENNEDY CAPITAL MANAGEMENT LLC | $1 849 430 | 385 298 | 0,37% | Acciones |
| Swiss National Bank | $1 375 200 | 286 500 | 0,28% | Acciones |
| Ledgewood Wealth Advisors, LLC | $1 336 493 | 278 436 | 0,27% | Acciones |
| FMR LLC | $1 277 232 | 266 090 | 0,26% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $1 265 688 | 263 685 | 0,26% | Acciones |
| Carrera Capital Advisors | $1 234 402 | 257 167 | 0,25% | Acciones |
| Quinn Opportunity Partners LLC | $1 225 027 | 255 214 | 0,25% | Acciones |
| D. E. Shaw & Co., Inc. | $1 209 614 | 252 003 | 0,24% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $1 161 682 | 242 017 | 0,23% | Acciones |
| Campbell & CO Investment Adviser LLC | $1 106 563 | 230 534 | 0,22% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 080 475 | 225 099 | 0,22% | Acciones |
| Squarepoint Ops LLC | $999 096 | 208 145 | 0,20% | Acciones |
| MARTINGALE ASSET MANAGEMENT L P | $926 880 | 193 100 | 0,19% | Acciones |
| RHUMBLINE ADVISERS | $909 224 | 189 423 | 0,18% | Acciones |
| STRS OHIO | $810 720 | 168 900 | 0,16% | Acciones |
| Bank of New York Mellon Corp | $801 067 | 166 889 | 0,16% | Acciones |
| Caption Management, LLC | $720 000 | 150 000 | 0,15% | Opción de compra |
| Caption Management, LLC | $720 000 | 150 000 | 0,15% | Opción de venta |
| Hudson Bay Capital Management LP | $720 000 | 150 000 | 0,15% | Acciones |
| Wealth Management Associates, Inc. | $710 376 | 147 995 | 0,14% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $701 467 | 146 139 | 0,14% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643 433 | 142 985 | 0,13% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $631 080 | 140 240 | 0,13% | Acciones |
| Connor, Clark & Lunn Investment Management Ltd. | $619 685 | 129 101 | 0,12% | Acciones |
| BlackRock, Inc. | $567 398 | 118 208 | 0,11% | Acciones |
| Front Row Advisors LLC | $516 035 | 110 500 | 0,10% | Acciones |
| BARCLAYS PLC | $499 320 | 104 025 | 0,10% | Acciones |
| Rafferty Asset Management, LLC | $490 416 | 102 170 | 0,10% | Acciones |
| MetLife Investment Management, LLC | $452 885 | 94 351 | 0,09% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $429 994 | 89 582 | 0,09% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $407 933 | 84 986 | 0,08% | Acciones |
| JBF Capital, Inc. | $385 349 | 80 281 | 0,08% | Acciones |
| Integrated Quantitative Investments LLC | $383 698 | 79 937 | 0,08% | Acciones |
| Virtus Investment Advisers, LLC | $368 674 | 76 807 | 0,07% | Acciones |
| XTX Topco Ltd | $365 808 | 76 210 | 0,07% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $317 832 | 66 215 | 0,06% | Acciones |
| Invesco Ltd. | $305 616 | 63 670 | 0,06% | Acciones |
| Rockefeller Capital Management L.P. | $302 400 | 63 000 | 0,06% | Acciones |
| Creative Planning | $298 133 | 62 111 | 0,06% | Acciones |
| JANUS HENDERSON GROUP PLC | $273 746 | 60 900 | 0,06% | Acciones |
| Quantinno Capital Management LP | $273 413 | 56 961 | 0,06% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265 118 | 55 233 | 0,05% | Acciones |
| Vanguard Global Advisers, LLC | $264 730 | 55 152 | 0,05% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255 936 | 53 320 | 0,05% | Acciones |
| Jump Financial, LLC | $255 178 | 53 162 | 0,05% | Acciones |
| PROFUND ADVISORS LLC | $254 482 | 53 017 | 0,05% | Acciones |
| WOLVERINE TRADING, LLC | $248 868 | 55 800 | 0,05% | Opción de compra |
| Police & Firemen's Retirement System of New Jersey | $248 203 | 51 709 | 0,05% | Acciones |
| Exome Asset Management LLC | $240 797 | 50 166 | 0,05% | Acciones |
| Magnetar Financial LLC | $225 922 | 47 067 | 0,05% | Acciones |
| State of New Jersey Common Pension Fund D | $221 602 | 46 167 | 0,04% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212 664 | 44 305 | 0,04% | Acciones |
| ALLSTATE CORP | $212 285 | 44 226 | 0,04% | Acciones |
| Quadrature Capital Ltd | $201 619 | 42 004 | 0,04% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189 475 | 39 474 | 0,04% | Acciones |
| ARIZONA STATE RETIREMENT SYSTEM | $189 110 | 39 398 | 0,04% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175 680 | 36 600 | 0,04% | Opción de compra |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171 936 | 35 820 | 0,03% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $169 286 | 35 268 | 0,03% | Acciones |
| INTECH INVESTMENT MANAGEMENT LLC | $167 208 | 34 835 | 0,03% | Acciones |
| Mitsubishi UFJ Trust & Banking Corp | $152 102 | 31 688 | 0,03% | Acciones |
| VOYA INVESTMENT MANAGEMENT LLC | $151 070 | 31 473 | 0,03% | Acciones |
| China Universal Asset Management Co., Ltd. | $150 902 | 31 438 | 0,03% | Acciones |
| Vanguard Investments Australia, Ltd. | $150 182 | 31 288 | 0,03% | Acciones |
| KLP KAPITALFORVALTNING AS | $148 320 | 30 900 | 0,03% | Acciones |
| Premier Path Wealth Partners, LLC | $144 000 | 30 000 | 0,03% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $139 675 | 29 099 | 0,03% | Acciones |
| SHERBROOKE PARK ADVISERS LLC | $134 627 | 27 989 | 0,03% | Acciones |
| EntryPoint Capital, LLC | $134 112 | 27 940 | 0,03% | Acciones |
Informantes de la empresa 25 insiders · 13 directivos · 11 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 24 de junio de 2019 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 de marzo de 2019 A | 341 396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 1 de marzo de 2019 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 de marzo de 2017 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 1 de marzo de 2019 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 1 de marzo de 2019 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 1 de marzo de 2019 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 de marzo de 2019 A | 1 503 403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 de diciembre de 2018 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 de abril de 2018 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 de marzo de 2017 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 de agosto de 2016 M | 42 097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 de marzo de 2016 A | — | 0 | 0 | $0 |
| Roger Sawhney | Consejero | 8 de junio de 2026 A | — | 0 | 0 | $0 |
| Robert A Beardsley | Consejero | 8 de junio de 2026 A | — | 0 | 0 | $0 |
| Frank Torti | Consejero | 26 de noviembre de 2018 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | Consejero | 19 de junio de 2018 A | — | 0 | 0 | $0 |
| Keith S Manchester | Consejero | 19 de junio de 2018 A | — | 0 | 0 | $0 |
| Daniel D Burgess | Consejero | 19 de junio de 2018 A | — | 0 | 0 | $0 |
| Herbert J Conrad | Consejero | 19 de junio de 2018 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | Consejero | 19 de junio de 2018 A | 1 000 | 0 | 0 | $0 |
| Frank Karbe | Consejero | 21 de junio de 2017 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Propietario del 10% | 18 de octubre de 2021 C | 38 847 462 | 0 | 0 | $0 |
| Andrew Lo | Propietario del 10% | 12 de enero de 2018 P | — | 0 | 0 | $0 |
| Patrick Machado | Propietario del 10% | 12 de enero de 2018 P | — | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 8 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 presentaciones | 28 de abril de 2026 | 8,00% | Enmienda | — | SEC |
| Roivant Sciences Ltd. ×14 presentaciones | 25 de febrero de 2025 | 20,50% | Enmienda | — | SEC |
| Patrick Machado ×4 presentaciones | 17 de julio de 2019 | — | Presentación inicial | — | SEC |
| Dr. Andrew Lo ×5 presentaciones | 17 de julio de 2019 | — | Presentación inicial | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 presentaciones | 12 de julio de 2019 | — | Presentación inicial | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 presentaciones | 12 de julio de 2019 | — | Presentación inicial | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 presentaciones | 12 de julio de 2019 | — | Presentación inicial | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 presentaciones | 12 de julio de 2019 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 34 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,66% | 58 600 NS | 30 de abril de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,50% | 24 523 SH | 8 de agosto de 2026 | Diario |
| IWC · iShares Trust | 0,17% | 546 359 SH | 8 de agosto de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,11% | 132 235 NS | 30 de abril de 2026 | N-PORT |
| SMMV · iShares Trust | 0,10% | 62 236 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 10 748 SH | 8 de agosto de 2026 | Diario |
| IBB · iShares Trust | 0,06% | 1 164 301 SH | 8 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172 487 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,04% | 1 441 824 SH | 8 de agosto de 2026 | Diario |
| BIB · ProShares Trust | 0,04% | 7 110 NS | 31 de mayo de 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,03% | 64 366 NS | 31 de mayo de 2026 | N-PORT |
| IWM · iShares Trust | 0,02% | 4 026 921 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925 044 SH | 8 de agosto de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 122 366 SH | 8 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,02% | 65 520 NS | 30 de abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,02% | 7 126 NS | 31 de mayo de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 734 401 NS | 31 de mayo de 2026 | N-PORT |
| ISCG · iShares Trust | 0,01% | 24 628 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,01% | 6 673 SH | 8 de agosto de 2026 | Diario |
| UWM · ProShares Trust | 0,01% | 5 554 NS | 31 de mayo de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1 810 587 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,01% | 430 244 SH | 8 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 64 437 NS | 30 de abril de 2026 | N-PORT |
| ISCV · iShares Trust | 0,01% | 13 314 SH | 8 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,01% | 11 503 SH | 8 de agosto de 2026 | Diario |
| URTY · ProShares Trust | 0,01% | 5 639 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 5 309 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 141 NS | 31 de mayo de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 266 009 SH | 8 de agosto de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 49 253 SH | 8 de agosto de 2026 | Diario |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 86 163 NS | 31 de mayo de 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 4 760 NS | 31 de mayo de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5 034 547 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13 683 SH | 8 de agosto de 2026 | Diario |